Abstract:Except a few tissues such as the cornea and cartilage that are avascular, blood vessels constitute a significant proportion of tissue masses in virtually all organs. Under physiological conditions, the adult vasculature remains quiescent to retain tissue and organ homeostatic functions. Too few or too many blood vessels are associated with the onset and progression of many diseases. In response to injuries, most tissues undergo repair by switching on angiogenesis, a key process of new blood vessel formation. [ 1 ] Similarly, angiogenesis is often active in pathological tissues, including tumors and ischemic tissues to aggravate disease progression. To induce neovascularization, angiogenic tissues produce various growth factors and cytokines that primarily target endothelial cells and perivascular cells. [ 2 ] Targeting these angiogenic factors provides an attractive approach for treatment of a number of malignant and non-malignant diseases such as cancer and ophthalmologic diseases. In fact, antiangiogenic drugs are routinely used in the clinic for the treatment of various cancers and ocular diseases. [ 2 ] Conversely, stimulation of angiogenesis by delivery of proangiogenic factors also provides an exciting opportunity for the treatment of ischemic diseases such as ischemic myocardium after cardiac infarction and wound healing. [ 3 ] In a series of review articles, we describe the updated knowledge of angiogenesis research and discuss clinical implications, challenging issues, and possible solutions. We provide a few examples of pro- and anti-angiogenic therapies for treatment of various diseases, including cancer, ophthalmological disease, cardiovascular disease, and metabolic disease [Figure 1]. Because the topic of angiogenesis in regulating lipid metabolism and metabolic diseases was recently discussed in another issue of the Chinese Medical Journal, [ 4 ] we exclude this topic in this issue. This special issue is also dedicated to honor and celebrate Dr. Judah Folkman for his initial hypothesis that has led to half a century of groundbreaking achievements in angiogenesis research and clinical success.

[Molecular pathogenesis of ocular vascular disease--anti-angiogenesis as a therapeutic concept]

Bioactive lipids in pathological retinopathy.

Contribution of VEGF and PEDF to Choroidal Angiogenesis: A Need for Balanced Expressions

Vascular endothelial growth factor in eye disease

Progress of Anti-Vascular Endothelial Growth Factor Therapy for Ocular Neovascular Disease: Benefits and Challenges

Pathological ocular angiogenesis in diabetes: A perspective of emerging paradigms and current evidence

Targeting angiogenesis in oncology, ophthalmology and beyond

Angiogenesis inhibitors: current & future directions

Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update

Anti-VEGF therapy in pediatric retinal and choroidal disease

Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration

[Diabetes and peripheral arterial occlusive disease: therapeutic potential and pro-angiogenic strategies]

PFKFB3 in neovascular eye disease: unraveling mechanisms and exploring therapeutic strategies

Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases

Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data

AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies

Molecular and Cellular Mechanisms Involved in the Pathophysiology of Retinal Vascular Disease—Interplay Between Inflammation and Oxidative Stress

Angiogenesis in diseases: A half-century excursion from the initial therapeutic concept to current clinical benefits

Up-to-date molecular medicine strategies for management of ocular surface neovascularization

Molecules related to diabetic retinopathy in the vitreous and involved pathways

Vascular endothelial growth factor and intraocular neovascularization